A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.
Urinary activity, reportedly a common feature of prostate-specific membrane antigen positron emission tomography (PSMA PET) radiopharmaceuticals, can have an adverse impact on imaging interpretation for detection of new or recurrent prostate cancer.
At initial staging, intense urinary activity with PET radiopharmaceuticals can obscure surrounding areas of the bladder, including the prostate, primary prostate lesions below the bladder, small lymph nodes around the bladder and invasion of the primary prostate tumor into surrounding structures such as the seminal vesicles, noted Phillip Kuo, M.D., Ph.D., F.A.C.R., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Dr. Kuo also pointed out that high urinary activity can make it more challenging to diagnose recurrence at the vesicourethral anastomosis, the most common site for prostate cancer recurrence.
(Editor’s note: For related content, see “PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer” and “Can an Emerging PSMA/PET Agent Improve Detection of Prostate Cancer Recurrence in Patients with Low PSAs?”)
However, in a recent study looking at phase 3 from the SPOTLIGHT and LIGHTHOUSE trials, Dr. Kuo and colleagues examined the use of the injectable PET imaging agent flotufolastat F 18 (POSLUMA®, Blue Earth Diagnostics) in 712 patients with either newly diagnosed or recurrent prostate cancer. The study findings, presented at the SNMMI conference, demonstrated that for 96 percent of the cohort, it was possible to distinguish between urinary activity and disease uptake.
“In the vast majority of the cases, urinary activity (with flotufolastat F 18) is low enough in the ureters and bladder that we think it will not potentially affect your ability to detect disease in the pelvis,” noted Dr. Kuo, a professor of medical imaging, biomedical engineering, and medicine at the University of Arizona College of Medicine.
For more insights from Dr. Kuo, watch the video below.
GE HealthCare to Launch PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
